Delix Therapeutics has raised $100 million in a Series C to catch up to a budding crop of psychedelics and neuroplastogen drugmakers, cashing in on a new wave of medicines for psychiatric and mental health ...

This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗